These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38673459)

  • 1. Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.
    Sharip MT; Nishad N; Pillay L; Goordoyel N; Goerge S; Subramanian S
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673459
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Parrot L; Dong C; Carbonnel F; Meyer A
    Aliment Pharmacol Ther; 2022 Feb; 55(4):380-388. PubMed ID: 34854100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
    Alrashed F; Abdullah I; Alfadhli A; Shehab M
    Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
    García MJ; Rivero M; Fernández-Clotet A; de Francisco R; Sicilia B; Mesonero F; de Castro ML; Casanova MJ; Bertoletti F; García-Alonso FJ; López-García A; Vicente R; Calvet X; Barreiro-de Acosta M; Ferrer Rosique J; Varela Trastoy P; Nuñez A; Ricart E; Riestra S; Arias García L; Rodríguez M; Arranz L; Pajares R; Mena R; Calafat M; Camo P; Bermejo F; Ponferrada Á; Madrigal RE; Llaó J; Sesé E; Sánchez E; Pineda Mariño JR; González Muñoza C; Carbajo López AY; Julián AB; Villoria Ferrer A; Baston-Rey I; Jara L; Almela P; Codesido L; de la Maza S; Leal C; Caballol B; Pérez-Martínez I; Vinuesa Campo R; Crespo J; Domènech E; Chaparro M; Gisbert JP
    J Crohns Colitis; 2024 Jan; 18(1):65-74. PubMed ID: 37522878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study.
    Yang H; Huang Z; Li M; Zhang H; Fu L; Wang X; Yang Q; He Y; Wu W; Jiang T; Sun Z; Zhang T; Lai D; Wu X; Shi L; Guo Q; Wu Y; Tang J; Chao K; Gao X
    EClinicalMedicine; 2023 Dec; 66():102337. PubMed ID: 38089859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Aliment Pharmacol Ther; 2020 May; 51(10):948-957. PubMed ID: 32249966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
    Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S
    Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A; Al Lehaibi LH; Alomar M; Aldhuwayan F; Alshouish S; Al-Ali AY; Almudhry Z; Almulhim A; Althagafi A; Aldosari S; AlAmeel T
    Saudi J Gastroenterol; 2024 Sep; 30(5):324-334. PubMed ID: 39157885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn's Disease Initiating Vedolizumab Versus Ustekinumab.
    Kappelman MD; Lewis JD; Zhang X; Lin FC; Weisbein L; Chen W; Burris J; Dorand JE; Parlett LE; Haynes K; Nair V; Kaul AF; Dobes A; Long MD
    Dig Dis Sci; 2023 Aug; 68(8):3413-3420. PubMed ID: 37115362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
    Gisbert JP; Chaparro M
    Drugs; 2023 Sep; 83(13):1179-1205. PubMed ID: 37505446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
    Onali S; Pugliese D; Caprioli FA; Orlando A; Biancone L; Nardone OM; Imperatore N; Fiorino G; Cappello M; Viola A; Principi MB; Bezzio C; Aratari A; Carparelli S; Mazzuoli S; Manguso F; Grossi L; Bodini G; Ribaldone D; Mocci G; Miranda A; Minerba L; Favale A; Grova M; Scucchi L; Segato S; Fries W; Castiglione F; Armuzzi A; Fantini MC;
    Am J Gastroenterol; 2022 Aug; 117(8):1279-1287. PubMed ID: 35467558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
    Kassouri L; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Dig Liver Dis; 2020 Oct; 52(10):1148-1155. PubMed ID: 32828693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab is associated with superior treatment persistence but not with higher remission rates
    Bacsur P; Matuz M; Resál T; Miheller P; Szamosi T; Schäfer E; Sarlós P; Iliás Á; Szántó K; Rutka M; Bálint A; Milassin Á; Fábián A; Bor R; Szepes Z; Molnár T; Farkas K
    Therap Adv Gastroenterol; 2022; 15():17562848221144349. PubMed ID: 36600684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.